Targeting G9a to develop Covid-19 and Long Covid treatments (biorxiv.org) 2 points by thenerdhead 2y ago ↗ HN
[–] thenerdhead 2y ago ↗ Inhibiting the G9a protein could help stop the COVID-19 virus from hijacking our cells to replicate, offering a new way to treat COVID-19.For Long COVID, targeting G9a might also help alleviate lingering symptoms by potentially reversing the virus's long-term impacts on our bodies.Based on a recent dissertation:https://www.cell.com/cell-chemical-biology/abstract/S2451-94...A novel G9a inhibitor has been identified that has been seen helpful for Alzheimer's as well:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690335/> Thus, in contrast to existing AD therapies that only slow one symptom (e.g., cognitive decline) targeting AD-activated G9a by the brain-penetrant drug MS1262 showed multifaceted effects that relieve all AD symptoms with minimum side effect.
1 comment
[ 19.5 ms ] story [ 212 ms ] threadFor Long COVID, targeting G9a might also help alleviate lingering symptoms by potentially reversing the virus's long-term impacts on our bodies.
Based on a recent dissertation:
https://www.cell.com/cell-chemical-biology/abstract/S2451-94...
A novel G9a inhibitor has been identified that has been seen helpful for Alzheimer's as well:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690335/
> Thus, in contrast to existing AD therapies that only slow one symptom (e.g., cognitive decline) targeting AD-activated G9a by the brain-penetrant drug MS1262 showed multifaceted effects that relieve all AD symptoms with minimum side effect.